- Home
- TZUP vs IFRX Comparison
TZUP vs IFRX Comparison
Compare TZUP & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TZUP
- IFRX
- Stock Information
- Founded
- TZUP 2020
- IFRX 2007
- Country
- TZUP United States
- IFRX Germany
- Employees
- TZUP N/A
- IFRX N/A
- Industry
- TZUP
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- TZUP
- IFRX Health Care
- Exchange
- TZUP NYSE
- IFRX Nasdaq
- Market Cap
- TZUP 66.7M
- IFRX 53.5M
- IPO Year
- TZUP N/A
- IFRX 2017
- Fundamental
- Price
- TZUP $9.95
- IFRX $0.88
- Analyst Decision
- TZUP
- IFRX Strong Buy
- Analyst Count
- TZUP 0
- IFRX 4
- Target Price
- TZUP N/A
- IFRX $7.75
- AVG Volume (30 Days)
- TZUP 315.9K
- IFRX 292.8K
- Earning Date
- TZUP 08-11-2025
- IFRX 08-07-2025
- Dividend Yield
- TZUP N/A
- IFRX N/A
- EPS Growth
- TZUP N/A
- IFRX N/A
- EPS
- TZUP N/A
- IFRX N/A
- Revenue
- TZUP $487.00
- IFRX $140,242.00
- Revenue This Year
- TZUP N/A
- IFRX N/A
- Revenue Next Year
- TZUP N/A
- IFRX $6,309.47
- P/E Ratio
- TZUP N/A
- IFRX N/A
- Revenue Growth
- TZUP N/A
- IFRX 30.90
- 52 Week Low
- TZUP $2.02
- IFRX $0.71
- 52 Week High
- TZUP $13.44
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- TZUP N/A
- IFRX 46.48
- Support Level
- TZUP N/A
- IFRX $0.78
- Resistance Level
- TZUP N/A
- IFRX $1.00
- Average True Range (ATR)
- TZUP 0.00
- IFRX 0.06
- MACD
- TZUP 0.00
- IFRX 0.03
- Stochastic Oscillator
- TZUP 0.00
- IFRX 47.87
About TZUP THUMZUP MEDIA CORP
Thumzup Media Corp operates in the social media branding and marketing industry. The company operates in a single business segment which is social media marketing. The Thumzup App works on both iPhone and Android mobile operating systems and connects brands and people who use and love these brands. The easy-to-use dashboard allows advertisers to programmatically customize their campaigns. Cash payments are made to App users/creators through Venmo and PayPal.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.